News

DS-5010 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer,

In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.

As per terms of the agreement, Gilead will pay $180.00 per Kite share in cash, representing a 29% premium to its closing price on 25 August. Based in

CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialization of

Mavenclad is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate

The Humira biosimilar can now be used in Europe for treating rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis

As per terms of the transaction, Regenxbio will pay $3.41 per Dimension share, which could be valued at around $86m. The acquisition will add Regenxbio with two product

Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth

The bispecific monoclonal antibody is intended to be used as a once-weekly subcutaneous treatment for the disease to cover adults, adolescents and children. According to Roche, emicizumab binds